Brief: Annovis Announces Open-Label Extension Study For Parkinson's Disease Patients
18/12/2025 23:25
Dec 18 (Reuters) - Annovis Bio Inc ANVS.N: ANNOVIS ANNOUNCES OPEN-LABEL EXTENSION STUDY FOR PARKINSON'S DISEASE PATIENTS ANNOVIS BIO INC - TO BEGIN OPEN-LABEL EXTENSION STUDY IN JANUARY 2026 Source text: ID:nGNX4ftB1J Further company coverage: ANVS.N ((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Annovis Bio
See all newsAnnovis Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Annovis Bio Q2 loss widens as R&D costs rise
Annovis Bio Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Annovis Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Accompanying Warrants
U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman